Lineage Cell Therapeutics, Inc. (LCTX)
0.8308
+0.01
(+1.32%)
USD |
NYAM |
Nov 20, 09:40
Lineage Cell Therapeutics Cash from Investing (Quarterly) : -5.147M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -5.147M |
| June 30, 2026 | 3.96M |
| March 31, 2026 | -2.326M |
| December 31, 2025 | -15.33M |
| September 30, 2025 | -0.012M |
| June 30, 2025 | -0.014M |
| March 31, 2025 | 1.903M |
| December 31, 2024 | 2.635M |
| September 30, 2024 | 3.888M |
| June 30, 2024 | -8.793M |
| March 31, 2024 | -0.038M |
| December 31, 2023 | 9.742M |
| September 30, 2023 | 2.122M |
| June 30, 2023 | 19.16M |
| March 31, 2023 | 15.43M |
| December 31, 2022 | -5.102M |
| September 30, 2022 | -40.91M |
| June 30, 2022 | -0.097M |
| March 31, 2022 | -0.046M |
| December 31, 2021 | -0.146M |
| September 30, 2021 | -0.068M |
| June 30, 2021 | -0.115M |
| March 31, 2021 | 10.07M |
| December 31, 2020 | 0.902M |
| September 30, 2020 | 0.178M |
| Date | Value |
|---|---|
| June 30, 2020 | 6.702M |
| March 31, 2020 | 5.256M |
| December 31, 2019 | 0.72M |
| September 30, 2019 | 13.48M |
| June 30, 2019 | -0.194M |
| March 31, 2019 | 2.946M |
| December 31, 2018 | 9.784M |
| September 30, 2018 | -0.138M |
| June 30, 2018 | -0.041M |
| March 31, 2018 | 2.211M |
| December 31, 2017 | -0.583M |
| September 30, 2017 | -0.258M |
| June 30, 2017 | -0.23M |
| March 31, 2017 | -9.154M |
| December 31, 2016 | -0.409M |
| September 30, 2016 | -0.464M |
| June 30, 2016 | -9.198M |
| March 31, 2016 | -0.818M |
| December 31, 2015 | 22.78M |
| September 30, 2015 | -2.027M |
| June 30, 2015 | -2.453M |
| March 31, 2015 | -0.3734M |
| December 31, 2014 | -0.2084M |
| September 30, 2014 | -0.0925M |
| June 30, 2014 | -0.1793M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Curis, Inc. | 0.00 |
| Armata Pharmaceuticals, Inc. | -0.091M |
| Voyager Therapeutics, Inc. | 29.27M |
| Black Diamond Therapeutics, Inc. | 4.218M |
| Invivyd, Inc. | -0.585M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.62M |
| Cash from Financing (Quarterly) | -0.023M |
| Free Cash Flow | -26.46M |
| Free Cash Flow Per Share (Quarterly) | -0.022 |
| Free Cash Flow to Equity (Quarterly) | -5.424M |
| Free Cash Flow to Firm (Quarterly) | -5.694M |
| Free Cash Flow Yield | -12.59% |